rs6259 — SHBG Asp356Asn

SHBG Asp356Asn — When an Extra Sugar Chain Changes Your Hormone Balance

Sex hormone-binding globulin is the liver's principal carrier for testosterone and estradiol. Only a tiny fraction of circulating testosterone — roughly 1–3% — is truly free and biologically active; SHBG tightly binds the rest, holding it in reserve. Rs6259 changes one amino acid deep in SHBG's C-terminal domain, and the consequence is biochemically elegant: the substitution creates a new site where sugar chains can attach to the protein. That extra glycosylation extends SHBG's survival in the bloodstream, pushing circulating SHBG concentrations higher — and shifting the balance between bound and free sex hormones.

The Mechanism

The variant converts aspartate to asparagine at position 356 of the SHBG precursor protein (position 327 in the older mature-protein numbering, giving rise to the historically common "Asp327Asn" or "D327N" designation in older literature). Asparagine at this position creates an [N-linked glycosylation consensus sequence | The sequence motif Asn-X-Ser/Thr, where X is any amino acid except proline, is recognized by the oligosaccharyltransferase complex in the endoplasmic reticulum as a site for N-linked sugar chain attachment] that the wild-type aspartate does not support.

A key nuance: [biochemical studies of SHBG glycosylation | Bocchinfuso et al. Endocrinology 1992, PMID 1425432; Hammond & Bocchinfuso J Steroid Biochem Mol Biol 1995, PMID 7626508] show that N-linked carbohydrate chains do NOT alter SHBG's steroid-binding affinity for testosterone or dihydrotestosterone. The extra glycosylation does not make SHBG bind more or less tightly to testosterone at the steroid-binding pocket (located in the N-terminal domain). Instead, the primary effect is on SHBG's metabolic fate: the additional sugar chain is thought to [increase protein half-life | by masking protease cleavage sites and modulating hepatic clearance receptors; the C-terminal domain containing this glycosylation site is also involved in SHBG's membrane receptor interactions] in the bloodstream, resulting in higher steady-state SHBG concentrations. Higher total SHBG means more testosterone is bound — reducing free androgen availability even though each SHBG molecule binds testosterone with unchanged affinity.

There is also a haplotype-level interaction: the [Thompson 2008 haplotype analysis | Thompson et al. Cancer Epidemiol Biomarkers Prev 2008, PMID 19064566] of 11 SHBG SNPs found that the rs6259 A allele (D356N) specifically neutralizes the SHBG-lowering effect of the rs858518/ rs727428 haplotype. When D356N is present on the same chromosomal background as the otherwise SHBG-lowering haplotype, the expected drop in SHBG does not occur — making rs6259 a key modifier of other SHBG variants' effects.

The Evidence

The clearest quantitative evidence comes from a 2009 study of men across three age groups¹¹ 2009 study of men across three age groups
Vanbillemont et al. Clin Endocrinol (Oxf) 2009, PMID 18681858, which found that A allele carriers in the middle-aged cohort had 14.2% higher SHBG (P<0.001) and 7.3% higher total testosterone (P=0.01) compared to GG homozygotes, with no significant change in free testosterone — consistent with the body maintaining free testosterone homeostasis through LH feedback while total SHBG rises.

A 2025 sibling study of 999 Dutch men²² 2025 sibling study of 999 Dutch men
Walravens et al. J Clin Endocrinol Metab 2025, PMID 38652149 confirmed that rs6259 A allele carriers showed higher SHBG and total testosterone with no clear effect on measured free testosterone. In the Dunning 2004 study of postmenopausal women³³ Dunning 2004 study of postmenopausal women
JNCI 2004, PMID 15199113, D356N was significantly associated with circulating SHBG levels (P=0.005) and the estradiol-to-SHBG ratio (P=0.01), explaining 0.6% of SHBG variance.

In the context of PCOS and metabolic syndrome, higher SHBG from the A allele appears protective. A Chinese Han male study (n=384)⁴⁴ Chinese Han male study (n=384)
Pang et al. Aging Clin Exp Res 2014, PMID 24671943 found A allele carriers had significantly lower metabolic syndrome risk (OR 0.56, 95% CI 0.33–0.96) alongside higher SHBG. A meta-analysis of 4,733 participants⁵⁵ meta-analysis of 4,733 participants
Li et al. Reprod Biomed Online 2021, PMID 33168491 found rs6259 was not significantly associated with PCOS risk overall — consistent with the larger Liao & Cao 2020 meta-analysis (1,660 PCOS cases, 1,312 controls, PMID 32589470) that also found no significant PCOS association. The mechanistic expectation (higher SHBG → lower free androgen index → protective against PCOS) is biologically plausible, but the genetic signal is not robust across all populations.

For breast cancer, a meta-analysis of 10,454 cases and 13,111 controls⁶⁶ meta-analysis of 10,454 cases and 13,111 controls
Zhou et al. Mol Biol Rep 2012, PMID 22711300 found no significant overall association with the Asp356Asn variant, but a protective effect emerged specifically in postmenopausal Asian women (dominant model OR 0.83, 95% CI 0.70–0.97). A Shanghai population-based study (1,106 cases, 1,180 controls) confirmed this pattern⁷⁷ confirmed this pattern
Cui et al. Cancer Epidemiol Biomarkers Prev 2005, PMID 15894658, finding OR 0.73 (95% CI 0.53–0.99) in postmenopausal women, with the strongest protection in lean women (OR 0.46) — consistent with the A allele raising SHBG, thereby sequestering more estradiol in the lower-estrogen postmenopausal environment.

An unexpected finding comes from prostate cancer: a Japanese study of 70 men on androgen deprivation therapy⁸⁸ Japanese study of 70 men on androgen deprivation therapy
Shiota et al. Clin Genitourin Cancer 2019, PMID 31036465 found that A allele carriers had dramatically worse outcomes, with HR 2.20 for progression (P=0.027) and HR 3.21 for mortality (P=0.012), despite comparable testosterone suppression across genotypes. The mechanism remains under investigation — one hypothesis is that higher SHBG levels in A allele carriers paradoxically maintain a reservoir of bioavailable androgen through SHBG membrane receptor-mediated signaling, which may fuel castration-resistant prostate cancer progression through non-classical androgen pathways.

For bone health, a study of postmenopausal women⁹⁹ study of postmenopausal women
Napoli et al. Bone 2009, PMID 19679209 found that A allele carriers had significantly lower bone mineral density at the total femur (P=0.004) and intertrochanter (P=0.002), without detectable differences in free estradiol — suggesting the skeletal effect may be mediated through SHBG's membrane receptor signaling or other estrogen-independent mechanisms.

Practical Implications

For most people, rs6259 GG genotype is the common variant (approximately 79% globally). A allele carriers — particularly AA homozygotes, who are rare (~1% of the population) — have measurably higher SHBG and a distinct hormone profile. The practical implications are most relevant for: (1) interpreting sex hormone panels (higher SHBG inflates total testosterone while free testosterone may be maintained); (2) prostate cancer treatment planning, where genotype may influence ADT response; and (3) breast cancer risk stratification in postmenopausal Asian women.

Interactions

rs727428 and rs858518 (SHBG regulatory variants): The Thompson 2008 haplotype analysis showed that rs6259 D356N neutralizes the SHBG-lowering haplotype formed by rs858518 and rs727428. A person carrying the A allele at rs6259 alongside the T allele at rs727428 or the A allele at rs858518 will partially or fully offset the expected SHBG reduction from those regulatory variants. This is relevant for anyone carrying risk genotypes at multiple SHBG loci — the net SHBG effect is the sum of all contributing variants, with rs6259 A acting as a counterweight to the rs727428/rs858518 lowering effect.

rs1799941 (SHBG promoter G-68A): This promoter variant in the hormones-sleep category also regulates SHBG levels through expression changes. Carriers of both rs1799941 A allele (higher SHBG) and rs6259 A allele (higher SHBG) would have additive SHBG-raising effects. For PCOS risk assessment and prostate cancer ADT planning, total SHBG genotype burden across all four SHBG variants (rs727428, rs858518, rs1799941, rs6259) provides the most informative picture.

Proposed interaction for supervisor review: Men with GA or AA genotype at rs6259 who are considering or undergoing androgen deprivation therapy for prostate cancer should have rs6259 genotype documented alongside baseline SHBG levels, as the Shiota 2019 data suggest this may be an independent prognostic factor for ADT response regardless of testosterone suppression depth.